Novo Nordisk: 80% of U.S. Wegovy patients with insurance paying less
than $25/month
Send a link to a friend
[November 03, 2023] COPENHAGEN/
LONDON (Reuters) - The majority of U.S. patients with health insurance
coverage taking Novo Nordisk's powerful weight-loss drug Wegovy are
paying less than $25 per month, a senior executive said on Thursday.
Doug Langa, Novo's vice president for North America, said most major
pharmacy benefit managers (PBMs) and health plans were covering the
hugely popular weekly injection.
He estimated that about 50 million Americans with obesity could be
eligible for Wegovy coverage under their health plans.
"And importantly we're seeing around 80% of the patients (with
insurance) are paying less than $25 for Wegovy," he said on a call with
analysts after the Danish drugmaker released record quarterly results.
[to top of second column]
|
A selection of injector pens for the Wegovy weight loss drug are
shown in this photo illustration in Chicago, Illinois, U.S., March
31, 2023. REUTERS/Jim Vondruska/Illustration/File Photo
The U.S. list price for Wegovy,
which launched in the country in June 2021, is $1,300 per month.
Novo cannot keep up with soaring demand and has warned that U.S.
shortages will continue in the short to medium term.
(Reporting by Jacob Gronholt-Pedersen and Maggie Fick; writing by
Josephine Mason; editing by Jason Neely)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |